Balyasny Asset Management LLC Cerevel Therapeutics Holdings, Inc. Transaction History

Balyasny Asset Management LLC

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$38.96 - $42.75 $18.7 Million - $20.6 Million	-480,808 Reduced 44.63%	596,407 $24.4 Million
Q1 2024 May 13, 2024	SELL	$40.88 - $43.27 $35.3 Million - $37.4 Million	-864,000 Reduced 44.51%	1,077,215 $45.5 Million
Q4 2023 Feb 14, 2024	BUY	$20.27 - $42.44 $38.7 Million - $81.1 Million	1,911,419 Added 6415.02%	1,941,215 $82.3 Million
Q3 2023 Nov 14, 2023	SELL	$20.26 - $31.91 $1.64 Million - $2.58 Million	-80,953 Reduced 73.1%	29,796 $650,000
Q2 2023 Aug 14, 2023	SELL	$23.9 - $35.38 $5.71 Million - $8.45 Million	-238,853 Reduced 68.32%	110,749 $3.52 Million
Q1 2023 May 15, 2023	BUY	$22.82 - $35.32 $7.98 Million - $12.3 Million	349,602 New	349,602 $8.53 Million

5.01M

3.3K

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

Stay updated on Balyasny Asset Management LLC with notifications on news.